The role of TRAIL death receptors in the treatment of hematological malignancies

Leukemia and Lymphoma

Volumn 49, Issue 1, 2008, Pages 27-35

  Henson, Elizabeth S ^a,b   Johnston, James B ^a,c   Gibson, Spencer B ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Department of Biochemistry and Medical Genetics ^*  (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Apoptosis; Therapy; TRAIL; TRAIL receptors; Transcription

Indexed keywords

ADENOVIRUS VECTOR; ARSENIC TRIOXIDE; BORTEZOMIB; CASPASE 10; CASPASE 8; CHLORAMBUCIL; CISPLATIN; CYTARABINE; DEATH RECEPTOR; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DEPSIPEPTIDE; DOXORUBICIN; ETOPOSIDE; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FLAVOPIRIDOL; FLUDARABINE; GAMMA INTERFERON; GEMCITABINE; GLUCOCORTICOID; IMATINIB; LEXATUMUMAB; LONAFARNIB; MAPATUMUMAB; MONOCLONAL ANTIBODY; PEMETREXED; RITUXIMAB; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CELL KILLING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; DRUG SENSITIZATION; ENZYME BINDING; ENZYME DEGRADATION; ENZYME SYNTHESIS; GENE ACTIVATION; GENE EXPRESSION REGULATION; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA CELL; LIPID RAFT; LUNG NON SMALL CELL CANCER; LYMPHOMA CELL; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; RECEPTOR BINDING; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM;

APOPTOSIS; GENE EXPRESSION REGULATION; HEMATOLOGIC NEOPLASMS; HUMANS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 38549132880     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701713655     Document Type: Review

References (66)

1. Ashkenazi, A. and Dixit, V. M. (1998) Death receptors: Signaling and modulation. Science, 281, pp. 1305-1308.
2. Kaufmann, S. H. and Steensma, D. P. (2005) On the TRAIL of a new therapy for leukemia. Leukemia, 19, pp. 2195-2202.
3. Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A. and Marsters, S. A. (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest, 104, pp. 155-162.
4. Kelley, S. K. and Ashkenazi, A. (2004) Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol, 4, pp. 333-339.
5. Liabakk, N. B. and Espevik, T. (2004) Monoclonal antibodies against TRAIL. Vitam Horm, 67, pp. 65-79.
6. Ashkenazi, A. and Dixit, V. M. (1999) Apoptosis control by death and decoy receptors. Curr Opin Cell Biol, 11, pp. 255-260.
7. Kabore, A. F., Johnston, J. B. and Gibson, S. B. (2004) Changes in the apoptotic and survival signaling in cancer cells and their potential therapeutic implications. Curr Cancer Drug Targets, 4, pp. 147-163.
8. Schneider, P., Thome, M., Burns, K., Bodmer, J. L., Hofmann, K. and Kataoka, T. (1997) TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity, 7, pp. 831-836.
9. Shetty, S., Gladden, J. B., Henson, E. S., Hu, X., Villanueva, J. and Haney, N. (2002) Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFκB activation in epithelial derived cell lines. Apoptosis, 7, pp. 413-420.
10. Aggarwal, B. B., Bhardwaj, U. and Takada, Y. (2004) Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors. Vitam Horm, 67, pp. 453-483.
11. Pietro, R Di and Zauli, G. (2004) Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol, 201, pp. 331-340.
12. Kim, K., Fisher, M. J., Xu, S. Q. and el-Deiry, W. S. (2000) Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res, 6, pp. 335-346.
13. MacFarlane, M., Harper, N., Snowden, R. T., Dyer, M. J., Barnett, G. A. and Pringle, J. H. (2002) Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene, 21, pp. 6809-6818.
14. Gomez-Benito, M., Martinez-Lorenzo, M. J., Anel, A., Marzo, I. and Naval, J. (2007) Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/ TRAIL. Exp Cell Res, 313, pp. 2378-2388.
15. Remacle-Bonnet, M., Garrouste, F., Baillat, G., Andre, F., Marvaldi, J. and Pommier, G. (2005) Membrane rafts segregate pro- from anti-apoptotic insulin-like growth factor-I receptor signaling in colon carcinoma cells stimulated by members of the tumor necrosis factor superfamily. Am J Pathol, 167, pp. 761-773.
16. Vanoosten, R. L., Moore, J. M., Ludwig, A. T. and Griffith, T. S. (2005) Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts. Mol Ther, 11, pp. 542-552.
17. Delmas, D., Rebe, C., Micheau, O., Athias, A., Gambert, P. and Grazide, S. (2004) Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene, 23, pp. 8979-8986.
18. Secchiero, P., Vaccarezza, M., Gonelli, A. and Zauli, G. (2004) TNF-related apoptosis-inducing ligand (TRAIL): A potential candidate for combined treatment of hematological malignancies. Curr Pharm Des, 10, pp. 3673-3681.
19. Merino, D., Lalaoui, N., Morizot, A., Schneider, P., Solary, E. and Micheau, O. (2006) Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol, 26, pp. 7046-7055.
20. Sheikh, M. S., Burns, T. F., Huang, Y., Wu, G. S., Amundson, S. and Brooks, K. S. (1998) p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res, 58, pp. 1593-1598.
21. Takimoto, R. and El-Deiry, W. S. (2000) Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene, 19, pp. 1735-1743.
22. Wen, J., Ramadevi, N., Nguyen, D., Perkins, C., Worthington, E. and Bhalla, K. (2000) Antileukemic drugs increase death receptor 5 levels and enhance apo-2L-induced apoptosis of human acute leukemia cells. Blood, 96, pp. 3900-3906.
23. Johnston, J. B., Kabore, A. F., Strutinsky, J., Hu, X., Paul, J. T. and Kropp, D. M. (2003) Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia. Oncogene, 22, pp. 8356-8369.
24. Meng, R. D. and El-Deiry, W. S. (2001) p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-γ. Exp Cell Res, 262, pp. 154-169.
25. Gibson, S. B., Oyer, R., Spalding, A. C., Anderson, S. M. and Johnson, G. L. (2000) Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol Cell Biol, 20, pp. 205-212.
26. Shetty, S., Gladden, J. B., Henson, E. S., Hu, X., Villanueva, J. and Haney, N. (2002) Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFκB activation in epithelial derived cell lines. Apoptosis, 7, pp. 413-420.
27. Yoshida, T., Maeda, A., Tani, N. and Sakai, T. (2001) Promoter structure and transcription initiation sites of the human death receptor 5/ TRAIL-R2 gene. FEBS Lett, 507, pp. 381-385.
28. Shetty, S., Graham, B. A., Brown, J. G., Hu, X., Vegh-Yarema, N. and Harding, G. (2005) Transcription factor NF-κB differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol Cell Biol, 25, pp. 5404-5416.
29. Zou, W., Liu, X., Yue, P., Zhou, Z., Sporn, M. B. and Lotan, R. (2004) c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1,9-dien-28-oate in human lung cancer cells. Cancer Res, 64, pp. 7570-7578.
30. Wang, Y., Engels, I. H., Knee, D. A., Nasoff, M., Deveraux, Q. L. and Quon, K. C. (2004) Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell, 5, pp. 501-512.
31. Sun, S. Y., Liu, X., Zou, W., Yue, P., Marcus, A. I. and Khuri, F. R. (2007) The farnesyltransferase inhibitor Lonafarnib induce CHOP-dependent expression of death receptor 5 leading to induction of apoptosis in human cancer cells. J Biol Chem, 282, pp. 18800-18809.
32. Kim, Y. H., Park, J. W., Lee, J. Y. and Kwon, T. K. (2004) Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells. Carcinogenesis, 25, pp. 1813-1820.
33. Baritaki, S., Huerta-Yepez, S., Sakai, T., Spandidos, D. A. and Bonavida, B. (2007) Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: Up-regulation of DR5 and inhibition of Yin Yang 1. Mol Cancer Ther, 6, pp. 1387-1399.
34. Guan, B., Yue, P., Lotan, R. and Sun, S. Y. (2002) Evidence that the human death receptor 4 is regulated by activator protein 1. Oncogene, 21, pp. 3121-3129.
35. Guan, B., Yue, P., Clayman, G. L. and Sun, S. Y. (2001) Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene. J Cell Physiol, 188, pp. 98-105.
36. Nguyen, T., Thomas, W., Zhang, X. D., Gray, C. and Hersey, P. (2000) Immunologically-mediated tumour cell apoptosis: The role of TRAIL in T cell and cytokine-mediated responses to melanoma. Forum (Genova), 10, pp. 243-252.
37. Zauli, G. and Secchiero, P. (2006) The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. Cytokine Growth Factor Rev, 17, pp. 245-257.
38. Sedger, L. M., Glaccum, M. B., Schuh, J. C., Kanaly, S. T., Williamson, E. and Kayagaki, N. (2002) Characterization of the in vivo function of TNF-α-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/ Apo2L gene-deficient mice. Eur J Immunol, 32, pp. 2246-2254.
39. Rubio-Moscardo, F., Blesa, D., Mestre, C., Siebert, R., Balasas, T. and Benito, A. (2005) Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes. Blood, 106, pp. 3214-3222.
40. Lee, S. H., Shin, M. S., Kim, H. S., Lee, H. K., Park, W. S. and Kim, S. Y. (1999) Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res, 59, pp. 5683-5686.
41. Lee, S. H., Shin, M. S., Kim, H. S., Lee, H. K., Park, W. S. and Kim, S. Y. (2001) Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma. Oncogene, 20, pp. 399-403.
42. Liu, L. G., Tanaka, H., Ito, K., Ito, T., Sultana, T. A. and Kyo, T. (2005) Absence of gene mutation in TRAIL receptor 1 (TRAIL-R1) and TRAIL receptor 2 (TRAIL-R2) in chronic myelogenous leukemia and myelodysplastic syndrome, and analysis of mRNA Expressions of TRAIL and TRAIL-related genes in chronic myelogenous leukemia. Acta Haematol, 113, pp. 113-123.
43. Wolf, S., Mertens, D., Pscherer, A., Schroeter, P., Winkler, D. and Grone, H. J. (2006) Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer. Int J Cancer, 118, pp. 1831-1835.
44. Zhang, L. and Fang, B. (2005) Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther, 12, pp. 228-237.
45. Falschlehner, C., Emmerich, C. H., Gerlach, B. and Walczak, H. (2007) TRAIL signalling: Decisions between life and death. Int J Biochem Cell Biol, 39, pp. 1462-1475.
46. Pedersen, I. M., Kitada, S., Leoni, L. M., Zapata, J. M., Karras, J. G. and Tsukada, N. (2002) Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood, 100, pp. 1795-1801.
47. Saxena, A., Viswanathan, S., Moshynska, O., Tandon, P., Sankaran, K. and Sheridan, D. P. (2004) Mcl-1 and Bcl-2/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia. Am J Hematol, 75, pp. 22-33.
48. Johnston, J. B., Paul, J. T., Neufeld, N. J., Haney, N., Kropp, D. M. and Hu, X. (2004) Role of myeloid cell factor-1 (Mcl-1) in chronic lymphocytic leukemia. Leuk Lymphoma, 45, pp. 2017-2027.
49. Gelinas, C. and White, E. (2005) BH3-only proteins in control: specificity regulates MCL-1 and BAK-mediated apoptosis. Genes Dev, 19, pp. 1263-1268.
50. Yagita, H., Takeda, K., Hayakawa, Y., Smyth, M. J. and Okumura, K. (2004) TRAIL and its receptors as targets for cancer therapy. Cancer Sci, 95, pp. 777-783.
51. Shrader, M., Pino, M. S., Lashinger, L., Bar-Eli, M., Adam, L. and Dinney, C. P. (2007) Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. Cancer Res, 67, pp. 1430-1435.
52. Wang, S. and El-Deiry, W. S. (2003) TRAIL and apoptosis induction by TNF-family death receptors. Oncogene, 22, pp. 8628-8633.
53. Lee, T. J., Jung, E. M., Lee, J. T., Kim, S., Park, J. W. and Choi, K. S. (2006) Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites. Mol Cancer Ther, 5, pp. 2737-2746.
54. Kim, D. M., Koo, S. Y., Jeon, K., Kim, M. H., Lee, J. and Hong, C. Y. (2003) Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-α or TNF-related apoptosis-inducing ligand in human cancer cell lines. Cancer Res, 63, pp. 621-626.
55. Akay, C. and Gazitt, Y. (2003) Arsenic trioxide selectively induces early and extensive apoptosis via the APO2/caspase-8 pathway engaging the mitochondrial pathway in myeloma cells with mutant p53. Cell Cycle, 2, pp. 358-368.
56. Liu, Q., Hilsenbeck, S. and Gazitt, Y. (2003) Arsenic trioxide-induced apoptosis in myeloma cells: P53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood, 101, pp. 4078-4087.
57. Nimmanapalli, R., Porosnicu, M., Nguyen, D., Worthington, E., O'Bryan, E. and Perkins, C. (2001) Cotreatment with STI-571 enhances tumor necrosis factor α-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Clin Cancer Res, 7, pp. 350-357.
58. Kabore, A. F., Sun, J., Hu, X., McCrea, K., Johnston, J. B. and Gibson, S. (2006) The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells. Apoptosis, 11, pp. 1175-1193.
59. MacFarlane, M., Inoue, S., Kohlhaas, S. L., Majid, A., Harper, N. and Kennedy, D. B. (2005) Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ, 12, pp. 773-782.
60. Insinga, A., Monestiroli, S., Ronzoni, S., Gelmetti, V., Marchesi, F. and Viale, A. (2005) Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med, 11, pp. 71-76.
61. Pan, Q., Liu, B., Liu, J., Cai, R., Wang, Y. and Qian, C. (2007) Synergistic induction of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying TRAIL. Mol Cell Biochem, 304, pp. 315-323.
62. Duiker, E. W., Mom, C. H., de Jong, S., Willemse, P. H., Gietema, J. A. and van der Zee, A. G. (2006) The clinical trail of TRAIL. Eur J Cancer, 42, pp. 2233-2240.
63. Yee, L., Fanale, M., Dimick, K., Calvert, S., Robbins, C. and Ing, J. (2007) A phase 1B safety and pharmacokinetic (PK) study of recombinant human Apo2L/TRAIL in combination with rituximab in patients with low grade non-Hodgkin lymphoma. p. Abstract 8078.
64. Georgakis, G. V., Li, Y., Humphreys, R., Andreeff, M., O'Brien, S. and Younes, M. (2005) Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: Induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol, 130, pp. 501-510.
65. Skic, B. I., Wakelee, H. A., Mehren, M. V., Lewis, N., Calvert, A. H. and Plummer, E. R. (2007) A phase 1b study to access the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2 in combination with gemitabine, pemetrexed, doxorubicin, or FOLFIRI. p. Abstract 14006.
66. Fanale, M. A. and Younes, A. (2007) Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs, 67, pp. 333-350.